載入中
NASDAQHealthcareDrug Manufacturers - General
最新資料
US$12.03
+US$0.04 · +0.33%
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
前收盤價
US$12.03
+US$0.04 · +0.33%
盤中時間採用ET。市場資料可能有所延遲。
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
日內區間
目前US$12.03
52週區間
目前US$12.03
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
48
合理估值
情緒
52
多空交錯
風險
43
風險偏高
動能
40
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
日內區間
目前US$12.03
52週區間
目前US$12.03
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.14億 USD | 2.29億 USD | 3.07億 USD | 3.69億 USD | 5.83億 USD |
| 銷貨成本 | 9277.8萬 USD | 1.47億 USD | 1.41億 USD | 1.27億 USD | 1.21億 USD |
| 毛利 | 1.21億 USD | 8138.2萬 USD | 1.66億 USD | 2.42億 USD | 4.62億 USD |
| 研究與開發 | 1980.6萬 USD | 2086.9萬 USD | 2221.9萬 USD | 3041.1萬 USD | 2930.7萬 USD |
| 銷售、一般及管理費用 | 1.15億 USD | 1.52億 USD | 2億 USD | 3.04億 USD | 4.08億 USD |
| 營業費用 | 1.35億 USD | 1.73億 USD | 2.22億 USD | 3.48億 USD | 4.51億 USD |
| 利息收入 | 1085.3萬 USD | 1340.3萬 USD | 1186.3萬 USD | 281.9萬 USD | 122萬 USD |
| 利息支出 | 7000 USD | 7000 USD | 8000 USD | 1.5萬 USD | 12.9萬 USD |
| 折舊和攤銷 | 302.8萬 USD | 291.5萬 USD | 296.5萬 USD | 309.6萬 USD | 285.7萬 USD |
| 營業利益 | −1394.1萬 USD | −9179.7萬 USD | −5661.6萬 USD | −1.06億 USD | 1050.2萬 USD |
| 淨利 | −3879.8萬 USD | −8218.3萬 USD | −5911.2萬 USD | −1.06億 USD | 772.9萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.17
下跌空間 81.96%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
